US ships out all re­main­ing sup­plies of the on­ly Covid mAb treat­ment that works against Omi­cron

Right as the new Omi­cron vari­ant is poised to in­crease rapid­ly across the US, the fed­er­al gov­ern­ment has ef­fec­tive­ly run out of the on­ly mon­o­clon­al an­ti­body treat­ment that works against it, and at least one ma­jor hos­pi­tal sys­tem is now halt­ing all mAb in­fu­sions.

Late last month, the fed­er­al gov­ern­ment paused ship­ments of Glax­o­SmithK­line and Vir’s mAb treat­ment sotro­vimab in or­der to con­serve sup­plies of the on­ly treat­ment that might work against the Omi­cron vari­ant. Last week, how­ev­er, HHS told End­points News that the move to hold back sotro­vimab was un­re­lat­ed to Omi­cron, and due to a sur­plus of Eli Lil­ly mAbs, which aren’t ef­fec­tive against Omi­cron.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.